Galnon

Last updated
Galnon
Galnon.svg
Identifiers
  • 9H-fluoren-9-ylmethyl N-[(2S)-1-([(2S)-6-amino-1-[(4-methyl-2-oxochromen-7- yl)amino]-1-oxohexan-2-yl]amino)-3-cyclohexyl-1-oxopropan-2-yl]carbamate
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
Formula C40H46N4O6
Molar mass 678.815 g·mol−1
3D model (JSmol)
  • Cc3cc(=O)oc6cc(ccc36)NC(=O)C(CCCCN)NC(=O)C(CC5CCCCC5)NC(=O)OCC1c2ccccc2-c4c1cccc4
  • InChI=1S/C40H46N4O6/c1-25-21-37(45)50-36-23-27(18-19-28(25)36)42-38(46)34(17-9-10-20-41)43-39(47)35(22-26-11-3-2-4-12-26)44-40(48)49-24-33-31-15-7-5-13-29(31)30-14-6-8-16-32(30)33/h5-8,13-16,18-19,21,23,26,33-35H,2-4,9-12,17,20,22,24,41H2,1H3,(H,42,46)(H,43,47)(H,44,48)/t34-,35-/m0/s1 X mark.svgN
  • Key:IKNOZZKXIDSTRN-PXLJZGITSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Galnon is a drug which acts as a selective, non-peptide agonist at the galanin receptors GALR. [1] [2] It has anticonvulsant, anxiolytic, anorectic and amnestic effects in animal studies. [3] [4] [5] [6] [7]

Related Research Articles

Dynorphins (Dyn) are a class of opioid peptides that arise from the precursor protein prodynorphin. When prodynorphin is cleaved during processing by proprotein convertase 2 (PC2), multiple active peptides are released: dynorphin A, dynorphin B, and α/β-neo-endorphin. Depolarization of a neuron containing prodynorphin stimulates PC2 processing, which occurs within synaptic vesicles in the presynaptic terminal. Occasionally, prodynorphin is not fully processed, leading to the release of “big dynorphin.” “Big Dynorphin” is a 32-amino acid molecule consisting of both dynorphin A and dynorphin B.

<span class="mw-page-title-main">5-HT receptor</span> Class of transmembrane proteins

5-HT receptors, 5-hydroxytryptamine receptors, or serotonin receptors, are a group of G protein-coupled receptor and ligand-gated ion channels found in the central and peripheral nervous systems. They mediate both excitatory and inhibitory neurotransmission. The serotonin receptors are activated by the neurotransmitter serotonin, which acts as their natural ligand.

<span class="mw-page-title-main">Neuropeptide Y</span> Mammalian protein found in Homo sapiens

Neuropeptide Y (NPY) is a 36 amino-acid neuropeptide that is involved in various physiological and homeostatic processes in both the central and peripheral nervous systems. NPY has been identified as the most abundant peptide present in the mammalian central nervous system, which consists of the brain and spinal cord. It is secreted alongside other neurotransmitters such as GABA and glutamate. 

<span class="mw-page-title-main">Vasopressin receptor 1B</span> Protein-coding gene in the species Homo sapiens

Vasopressin V1b receptor (V1BR) also known as vasopressin 3 receptor (VPR3) or antidiuretic hormone receptor 1B is a protein that in humans is encoded by the AVPR1B gene.

<span class="mw-page-title-main">Galanin</span>

Galanin is a neuropeptide encoded by the GAL gene, that is widely expressed in the brain, spinal cord, and gut of humans as well as other mammals. Galanin signaling occurs through three G protein-coupled receptors.

The galanin receptor is a G protein-coupled receptor, or metabotropic receptor which binds galanin.

<span class="mw-page-title-main">Neuropeptide S receptor</span> Protein-coding gene in the species Homo sapiens

The neuropeptide S receptor (NPSR) is a member of the G-protein coupled receptor superfamily of integral membrane proteins which binds neuropeptide S (NPS). It was formerly an orphan receptor, GPR154, until the discovery of neuropeptide S as the endogenous ligand. Increased expression of this gene in ciliated cells of the respiratory epithelium and in bronchial smooth muscle cells is associated with asthma. This gene is a member of the G protein-coupled receptor 1 family and encodes a plasma membrane protein. Mutations in this gene have also been associated with this disease.

<span class="mw-page-title-main">Hypocretin (orexin) receptor 2</span> Protein-coding gene in the species Homo sapiens

Orexin receptor type 2 (Ox2R or OX2), also known as hypocretin receptor type 2 (HcrtR2), is a protein that in humans is encoded by the HCRTR2 gene.

<span class="mw-page-title-main">Y-23684</span>

Y-23684 is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.

<span class="mw-page-title-main">Eglumetad</span>

Eglumetad is a research drug developed by Eli Lilly and Company, which is being investigated for its potential in the treatment of anxiety and drug addiction. It is a glutamate derived compound and its mode of action implies a novel mechanism.

<span class="mw-page-title-main">JTC-801</span> Chemical compound

JTC-801 is an opioid analgesic drug used in scientific research.

<span class="mw-page-title-main">ELB-139</span>

ELB-139 (LS-191,811) is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.

<span class="mw-page-title-main">TPA-023</span> Chemical compound

TPA-023 (MK-0777) is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. It is a subtype-selective, mixed allosteric modular at the benzodiazepine location on GABAA receptors, where it acts as a partial agonist at the α2 and α3 subtypes, but as a silent antagonist at α1 and α5 subtypes. It has primarily anxiolytic and anticonvulsant effects in animal tests, but with no sedative effects even at 50 times the effective anxiolytic dose.

<span class="mw-page-title-main">Ro64-6198</span> Chemical compound

Ro64-6198 is a nociceptoid drug used in scientific research. It acts as a potent and selective agonist for the nociceptin receptor, also known as the ORL-1 receptor, with over 100x selectivity over other opioid receptors. It produces anxiolytic effects in animal studies equivalent to those of benzodiazepine drugs, but has no anticonvulsant effects and does not produce any overt effects on behaviour. However it does impair short-term memory, and counteracts stress-induced anorexia. It also has antitussive effects, and reduces the rewarding and analgesic effects of morphine, although it did not prevent the development of dependence. It has been shown to reduce alcohol self-administration in animals and suppressed relapses in animal models of alcoholism, and ORL-1 agonists may have application in the treatment of alcoholism.

<span class="mw-page-title-main">MTEP</span>

3-( ethynyl)pyridine (MTEP) is a research drug that was developed by Merck & Co. as a selective allosteric antagonist of the metabotropic glutamate receptor subtype mGluR5. Identified through structure-activity relationship studies on an older mGluR5 antagonist MPEP, MTEP has subsequently itself acted as a lead compound for newer and even more improved drugs.

<span class="mw-page-title-main">BIIE-0246</span>

BIIE-0246 is a drug used in scientific research which acts as a potent and selective antagonist for the Neuropeptide Y receptor Y2. It was one of the first non-peptide Y2-selective antagonists developed, and remains among the most widely used tools for studying this receptor. It has been used to demonstrate a role for the Y2 subtype as a presynaptic autoreceptor limiting further neuropeptide Y release, as well as modulating dopamine and acetylcholine release. It has also been shown to produce several behavioural effects in animals, including reducing alcohol consumption in addicted rats and anxiolytic effects, although while selective Y2 agonists are expected to be useful as anorectics, BIIE-0246 did not appear to increase appetite when administered alone.

<span class="mw-page-title-main">Neuropeptide S</span> Protein-coding gene in the species Homo sapiens

Neuropeptide S (NPS) is a neuropeptide found in human and mammalian brain, mainly produced by neurons in the amygdala and between Barrington's nucleus and the locus coeruleus, although NPS-responsive neurons extend projections into many other brain areas. NPS binds specifically to a G protein-coupled receptor, NPSR. Animal studies show that NPS suppresses anxiety and appetite, induces wakefulness and hyperactivity, including hyper-sexuality, and plays a significant role in the extinction of conditioned fear. It has also been shown to significantly enhance dopamine activity in the mesolimbic pathway, and inhibits motility and increases permeability in neurocrine fashion acting through NO in the myenteric plexus in rats and humans.

<span class="mw-page-title-main">Galmic</span> Chemical compound

Galmic is a drug which acts as a selective, non-peptide agonist at the galanin receptors GALR. It has anticonvulsant, antidepressant and analgesic effects in animal studies, but also inhibits memory functions.

Osemozotan (MKC-242) is a selective 5-HT1A receptor agonist with some functional selectivity, acting as a full agonist at presynaptic and a partial agonist at postsynaptic 5-HT1A receptors. 5-HT1A receptor stimulation influences the release of various neurotransmitters including serotonin, dopamine, norepinephrine, and acetylcholine. 5-HT1A receptors are inhibitory G protein-coupled receptor. Osemozotan has antidepressant, anxiolytic, antiobsessional, serenic, and analgesic effects in animal studies, and is used to investigate the role of 5-HT1A receptors in modulating the release of dopamine and serotonin in the brain, and their involvement in addiction to abused stimulants such as cocaine and methamphetamine.

<span class="mw-page-title-main">HA-966</span>

HA-966 or (±) 3-Amino-1-hydroxy-pyrrolidin-2-one is a molecule used in scientific research as a glycine receptor and NMDA receptor antagonist / low efficacy partial agonist. It has neuroprotective and anticonvulsant, anxiolytic, antinociceptive and sedative / hypnotic effects in animal models. Pilot human clinical trials in the early 1960s showed that HA-966 appeared to benefit patients with tremors of extrapyramidal origin.

References

  1. ↑ Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K, Hellberg S, Pooga M, Tolf BR, Shi TS, Hökfelt T, Wasterlain C, Bartfai T, Langel U (May 2002). "Anticonvulsant activity of a nonpeptide galanin receptor agonist". Proceedings of the National Academy of Sciences of the United States of America. 99 (10): 7136–41. doi: 10.1073/pnas.102163499 . PMC   124541 . PMID   12011470.
  2. ↑ Sollenberg U, Bartfai T, Langel U (June 2005). "Galnon--a low-molecular weight ligand of the galanin receptors". Neuropeptides. 39 (3): 161–3. doi:10.1016/j.npep.2004.12.019. PMID   15944006. S2CID   40987364.
  3. ↑ Abramov U, Florén A, Echevarria DJ, Brewer A, Manuzon H, Robinson JK, Bartfai T, Vasar E, Langel U (February 2004). "Regulation of feeding by galnon". Neuropeptides. 38 (1): 55–61. doi:10.1016/j.npep.2004.01.001. PMID   15003717. S2CID   38073212.
  4. ↑ Badie-Mahdavi H, Behrens MM, Rebek J, Bartfai T (June 2005). "Effect of galnon on induction of long-term potentiation in dentate gyrus of C57BL/6 mice". Neuropeptides. 39 (3): 249–51. doi:10.1016/j.npep.2004.12.010. PMID   15944018. S2CID   2142254.
  5. ↑ Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE (October 2007). "Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon". Neuropeptides. 41 (5): 307–20. doi:10.1016/j.npep.2007.05.001. PMID   17637475. S2CID   25988178.
  6. ↑ Kozlovsky N, Matar MA, Kaplan Z, Zohar J, Cohen H (March 2009). "The role of the galaninergic system in modulating stress-related responses in an animal model of posttraumatic stress disorder". Biological Psychiatry. 65 (5): 383–91. doi:10.1016/j.biopsych.2008.10.034. PMID   19095221. S2CID   24537435.
  7. ↑ Narasimhaiah R, Kamens HM, Picciotto MR (May 2009). "Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice". Psychopharmacology. 204 (1): 95–102. doi:10.1007/s00213-008-1438-7. PMC   2872184 . PMID   19099295.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.